PD-L2 expression as a potential predictive biomarker for the response to anti-PD-1 drugs in patients with non-small cell lung cancer

Shinkichi Takamori, Kazuki Takada, Gouji Toyokawa, Koichi Azuma, Mototsugu Shimokawa, Tomoko Jogo, Yuichi Yamada, Fumihiko Hirai, Tetsuzo Tagawa, Akihiko Kawahara, Jun Akiba, Isamu Okamoto, Yoichi Nakanishi, Yoshinao Oda, Tomoaki Hoshino, Yoshihiko Maehara

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background/Aim: To investigate the role of programmed cell death-ligand 2 (PD-L2) expression as a predictive biomarker for response to anti-programmed cell death-1 (PD-1) drugs in patients with non-small cell lung cancer (NSCLC). Patients and Methods: Ten patients who had undergone curative lung resection and received the anti-PD-1 drugs for the recurrence were enrolled. The cut-off value for PD-L2 (antibody clone 176611) expression on tumor cells was set at 50%. Tumor response was evaluated according to immune-related response criteria. Results: Seven patients (70.0%) were positive for PD-L2. The response rates were 28.6% (2/7) and 33.3% (1/3) in patients with PD-L2-positive and PD-L2-negative NSCLC, respectively. Disease control was obtained in 2 patients despite the programmed cell deathligand 1 (PD-L1)-negativity (antibody clone 22C3: 0%, antibody clone SP142: 0%), and these tumors expressed PDL2 (=1%). Conclusion: PD-L2 expression may be a target of immunotherapy in patients with PD-L1-negative NSCLC.

Original languageEnglish
Pages (from-to)5897-5901
Number of pages5
JournalAnticancer research
Volume38
Issue number10
DOIs
Publication statusPublished - Oct 1 2018

Fingerprint

Non-Small Cell Lung Carcinoma
Cell Death
Biomarkers
Ligands
Pharmaceutical Preparations
Clone Cells
Antibodies
Neoplasms
Immunotherapy
Recurrence
Lung

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

PD-L2 expression as a potential predictive biomarker for the response to anti-PD-1 drugs in patients with non-small cell lung cancer. / Takamori, Shinkichi; Takada, Kazuki; Toyokawa, Gouji; Azuma, Koichi; Shimokawa, Mototsugu; Jogo, Tomoko; Yamada, Yuichi; Hirai, Fumihiko; Tagawa, Tetsuzo; Kawahara, Akihiko; Akiba, Jun; Okamoto, Isamu; Nakanishi, Yoichi; Oda, Yoshinao; Hoshino, Tomoaki; Maehara, Yoshihiko.

In: Anticancer research, Vol. 38, No. 10, 01.10.2018, p. 5897-5901.

Research output: Contribution to journalArticle

Takamori, S, Takada, K, Toyokawa, G, Azuma, K, Shimokawa, M, Jogo, T, Yamada, Y, Hirai, F, Tagawa, T, Kawahara, A, Akiba, J, Okamoto, I, Nakanishi, Y, Oda, Y, Hoshino, T & Maehara, Y 2018, 'PD-L2 expression as a potential predictive biomarker for the response to anti-PD-1 drugs in patients with non-small cell lung cancer', Anticancer research, vol. 38, no. 10, pp. 5897-5901. https://doi.org/10.21873/anticanres.12933
Takamori, Shinkichi ; Takada, Kazuki ; Toyokawa, Gouji ; Azuma, Koichi ; Shimokawa, Mototsugu ; Jogo, Tomoko ; Yamada, Yuichi ; Hirai, Fumihiko ; Tagawa, Tetsuzo ; Kawahara, Akihiko ; Akiba, Jun ; Okamoto, Isamu ; Nakanishi, Yoichi ; Oda, Yoshinao ; Hoshino, Tomoaki ; Maehara, Yoshihiko. / PD-L2 expression as a potential predictive biomarker for the response to anti-PD-1 drugs in patients with non-small cell lung cancer. In: Anticancer research. 2018 ; Vol. 38, No. 10. pp. 5897-5901.
@article{b5ef440dda5440dbbe046f2aefd44a3a,
title = "PD-L2 expression as a potential predictive biomarker for the response to anti-PD-1 drugs in patients with non-small cell lung cancer",
abstract = "Background/Aim: To investigate the role of programmed cell death-ligand 2 (PD-L2) expression as a predictive biomarker for response to anti-programmed cell death-1 (PD-1) drugs in patients with non-small cell lung cancer (NSCLC). Patients and Methods: Ten patients who had undergone curative lung resection and received the anti-PD-1 drugs for the recurrence were enrolled. The cut-off value for PD-L2 (antibody clone 176611) expression on tumor cells was set at 50{\%}. Tumor response was evaluated according to immune-related response criteria. Results: Seven patients (70.0{\%}) were positive for PD-L2. The response rates were 28.6{\%} (2/7) and 33.3{\%} (1/3) in patients with PD-L2-positive and PD-L2-negative NSCLC, respectively. Disease control was obtained in 2 patients despite the programmed cell deathligand 1 (PD-L1)-negativity (antibody clone 22C3: 0{\%}, antibody clone SP142: 0{\%}), and these tumors expressed PDL2 (=1{\%}). Conclusion: PD-L2 expression may be a target of immunotherapy in patients with PD-L1-negative NSCLC.",
author = "Shinkichi Takamori and Kazuki Takada and Gouji Toyokawa and Koichi Azuma and Mototsugu Shimokawa and Tomoko Jogo and Yuichi Yamada and Fumihiko Hirai and Tetsuzo Tagawa and Akihiko Kawahara and Jun Akiba and Isamu Okamoto and Yoichi Nakanishi and Yoshinao Oda and Tomoaki Hoshino and Yoshihiko Maehara",
year = "2018",
month = "10",
day = "1",
doi = "10.21873/anticanres.12933",
language = "English",
volume = "38",
pages = "5897--5901",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

TY - JOUR

T1 - PD-L2 expression as a potential predictive biomarker for the response to anti-PD-1 drugs in patients with non-small cell lung cancer

AU - Takamori, Shinkichi

AU - Takada, Kazuki

AU - Toyokawa, Gouji

AU - Azuma, Koichi

AU - Shimokawa, Mototsugu

AU - Jogo, Tomoko

AU - Yamada, Yuichi

AU - Hirai, Fumihiko

AU - Tagawa, Tetsuzo

AU - Kawahara, Akihiko

AU - Akiba, Jun

AU - Okamoto, Isamu

AU - Nakanishi, Yoichi

AU - Oda, Yoshinao

AU - Hoshino, Tomoaki

AU - Maehara, Yoshihiko

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Background/Aim: To investigate the role of programmed cell death-ligand 2 (PD-L2) expression as a predictive biomarker for response to anti-programmed cell death-1 (PD-1) drugs in patients with non-small cell lung cancer (NSCLC). Patients and Methods: Ten patients who had undergone curative lung resection and received the anti-PD-1 drugs for the recurrence were enrolled. The cut-off value for PD-L2 (antibody clone 176611) expression on tumor cells was set at 50%. Tumor response was evaluated according to immune-related response criteria. Results: Seven patients (70.0%) were positive for PD-L2. The response rates were 28.6% (2/7) and 33.3% (1/3) in patients with PD-L2-positive and PD-L2-negative NSCLC, respectively. Disease control was obtained in 2 patients despite the programmed cell deathligand 1 (PD-L1)-negativity (antibody clone 22C3: 0%, antibody clone SP142: 0%), and these tumors expressed PDL2 (=1%). Conclusion: PD-L2 expression may be a target of immunotherapy in patients with PD-L1-negative NSCLC.

AB - Background/Aim: To investigate the role of programmed cell death-ligand 2 (PD-L2) expression as a predictive biomarker for response to anti-programmed cell death-1 (PD-1) drugs in patients with non-small cell lung cancer (NSCLC). Patients and Methods: Ten patients who had undergone curative lung resection and received the anti-PD-1 drugs for the recurrence were enrolled. The cut-off value for PD-L2 (antibody clone 176611) expression on tumor cells was set at 50%. Tumor response was evaluated according to immune-related response criteria. Results: Seven patients (70.0%) were positive for PD-L2. The response rates were 28.6% (2/7) and 33.3% (1/3) in patients with PD-L2-positive and PD-L2-negative NSCLC, respectively. Disease control was obtained in 2 patients despite the programmed cell deathligand 1 (PD-L1)-negativity (antibody clone 22C3: 0%, antibody clone SP142: 0%), and these tumors expressed PDL2 (=1%). Conclusion: PD-L2 expression may be a target of immunotherapy in patients with PD-L1-negative NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=85054083876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054083876&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12933

DO - 10.21873/anticanres.12933

M3 - Article

C2 - 30275216

AN - SCOPUS:85054083876

VL - 38

SP - 5897

EP - 5901

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -